Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIF

IMV Inc. is a Canada-based company. The Company has no business operations.

GREY:IMVIF - Post Discussion

IMV Inc > Interesting (and hidden) data
View:
Post by Breakthorough on Sep 10, 2022 3:43pm

Interesting (and hidden) data

If you go to page 19 of last Corporate presentation, you will find, on the left side, "Further evaluating data from SPIReL" (Phase 2a of DLBCL, being Phase 2b the VITALIZE TRIAL). There you can see something not announced till now: mOS In PD-L1+ patients of 17'4 months. That's REALLY GOOD. To have an idea, think that CAR T has generally a mOS of 12 months in the trials (f.ex. JULIET Trial), and 15'8 months in this study of patients treated with commercial CAR T: https://ashpublications.org/bloodadvances/article/4/19/4669/463994/Outcomes-in-patients-with-DLBCL-treated-with Mvp-S+KTR is, needless to say, administered AGTER CAR T (or to people not eligible for CAR T, if I remember well)
Comment by Biotech010 on Sep 11, 2022 1:36pm
nice find! I cant find the poster online formulier todays esmo conference.... anyone did???
Comment by Hideaway on Sep 11, 2022 2:47pm
We’ll present at @myESMO 's #ESMO22 on our Phase 2b study, VITALIZE, investigating our lead DPX® product in #DLBCL. We're looking forward to discussing the ongoing study. Meet us there: https://bit.ly/3w6exjL #IMVisitingESMO22
Comment by Hideaway on Sep 11, 2022 2:55pm
According to the tweet, IMV have presented at the ESMO 11 am ECT. Hope they will post the presentation later today or tomorrow.I also checked the conference agenda for today and could not see any mention of IMV.
Comment by bikkel78 on Sep 11, 2022 3:31pm
we just have to wait :)
Comment by Hideaway on Sep 12, 2022 9:28am
No mention of ESMO presentation yet  with only minutes prior to markets opening.If IVM has any interest in promoting the Company one would think they would be eager to release information early especially on a study for which we were all awaiting early results on.The Wainwright presentation is today so I hope we hear some positive announcements in the next few hours.
Comment by Breakthorough on Sep 12, 2022 9:32am
The ESMO presentation (the PDF is already ay IMV website) was just a presentation of the Trial. The preliminary results have been announced for 3Q, though in the last corporate presentation they are announced for 2H.
Comment by Hideaway on Sep 12, 2022 10:45am
Thanks Breakthrough.The wording on their tweet was what confused me.If it was just a repeat of the August 22 presentation,there would be no new info given in the ESMO presentation. Is the PDF you referred to the Aug. 22 presentation? I was not able to find one specific to the ESMO conference on their site.
Comment by Breakthorough on Sep 12, 2022 10:49am
It is here: https://www.imv-inc.com/the-dpx-platform/scientific-publications-posters
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities